U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900088) titled 'Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients' on Dec. 27, 2024.
Brief Summary: Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
Study Start Date: April 25
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Intervention:
DRUG: Selinexor
maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation
Recruitment Status:...